Connect Biopharma Holdings Limited (CNTB)
| Market Cap | 142.43M |
| Revenue (ttm) | 64,000 -99.8% |
| Net Income | -55.48M |
| EPS | -1.00 |
| Shares Out | 56.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,479 |
| Open | 2.640 |
| Previous Close | 2.520 |
| Day's Range | 2.420 - 2.640 |
| 52-Week Range | 1.230 - 3.820 |
| Beta | -0.18 |
| Analysts | Strong Buy |
| Price Target | 8.67 (+244.05%) |
| Earnings Date | May 14, 2026 |
About CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Financial Performance
In 2025, CNTB's revenue was $64,000, a decrease of -99.75% compared to the previous year's $26.03 million. Losses were -$55.48 million, 255.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CNTB stock is "Strong Buy." The 12-month stock price target is $8.67, which is an increase of 244.05% from the latest price.
News
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans...
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breakin...
Connect Biopharma Holdings Transcript: Study result
Rademikibart IV showed rapid, robust FEV1 improvements in asthma and COPD, with effects seen within 15 minutes and sustained for 29 days, outperforming existing therapies. Atopic dermatitis results demonstrated high long-term efficacy and low conjunctivitis rates. Top-line results from ongoing acute exacerbation studies are expected mid-year.
Connect Biopharma Announces $20.2 Million Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“C...
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients –
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV 1 with many patients experiencing ...
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on tran...
Connect Biopharma Holdings Transcript: Leerink Global Healthcare Conference 2026
A next-generation IL-4 receptor antibody is advancing in acute asthma and COPD, with rapid onset and unique efficacy and safety profiles. Phase II data and IV study results are expected soon, while a China partnership could yield significant milestones and global expansion opportunities.
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused o...
Connect Biopharma Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rademikibart, a next-generation IL-4Rα antibody, is advancing in acute and chronic asthma and COPD, showing rapid efficacy and a differentiated safety profile. Acute studies are expected to drive both market adoption and regulatory progress, with key data and milestones anticipated midyear.
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –
Connect Biopharma Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference
A next-generation IL-4 receptor alpha antibody is being developed for rapid-onset treatment of acute asthma and COPD, targeting a large unmet need in acute care. Phase 2 global trials are underway, with key data expected in the first half of next year, and regulatory engagement planned soon after.
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademikibart f...
Connect Biopharma Holdings Transcript: Status Update
Rademikibart is positioned as a first-in-class biologic for acute asthma and COPD, with rapid efficacy, a favorable safety profile, and no direct competitors for acute treatment. Phase II data is expected in the first half of next year, and the company is well-funded with strong partnership prospects.
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest improvements observed in those with elevated baseline levels of key type 2 ...
Connect Biopharma Holdings Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Connect has transformed into a U.S.-focused biotech, advancing rademikibart for acute asthma exacerbations with rapid onset and a differentiated safety profile. The acute indication is positioned as a gateway to chronic use, with strong clinician interest and a solid cash runway into 2027.
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans...
Connect Biopharma Holdings Transcript: Cantor Global Healthcare Conference 2025
Leadership refocused operations to the U.S. and advanced rademikibart for acute asthma and COPD, targeting a large unmet market. Phase II trials are underway with top-line data expected next year, and financials support ongoing development.
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transformi...
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transf...
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14...
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the...
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation...